Novosom Overview

  • Founded
  • 1999
  • Status
  • Acquired/​Merged
  • Employees
  • 11
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $5M
Latest Deal Amount

Novosom General Information


Developer of biopharmaceutical-based charge-reversible liposomal technology designed for the delivery of DNA based therapeutics. The company offers Smartycles, a technology that allows the delivery of active substances, such as siRNA, antisense and decoy oligonucleotides inside the cell either for topical or systemic applications and CD40 antagonist, an antisense oligonucleotide for inflammatory diseases and B-cell cancers. It also provides therapeutic products addressing inflammation, oncology and liver diseases.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Therapeutic Devices
Primary Office
  • Weinbergweg 22
  • 06120 Halle
  • Germany
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Novosom Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 28-Jul-2010 $5M 000 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view Novosom’s complete valuation and funding history, request access »

Novosom Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novosom Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
IBG Beteiligungsgesellschaft Sachsen-Anhalt Venture Capital Minority 000 0000 000000 0
bmp Ventures Venture Capital Minority 000 0000 000000 0
To view Novosom’s complete investors history, request access »